{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:15:45Z","timestamp":1772576145866,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T00:00:00Z","timestamp":1504483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.lungcan.2017.08.024","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T20:49:14Z","timestamp":1504298954000},"page":"14-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation"],"prefix":"10.1016","volume":"113","author":[{"given":"Eric","family":"Santoni-Rugiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Grauslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linea C.","family":"Melchior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junia C.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens B.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edyta M.","family":"Urbanska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.08.024_bib0005","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/PPO.0000000000000147","article-title":"Epidermal growth factor receptor-mutant lung cancer: new drugs, new resistance mechanisms, and future treatment options","volume":"21","author":"Piotrowska","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.lungcan.2017.08.024_bib0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.21037\/tlcr.2016.07.10","article-title":"Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors","volume":"5","author":"Dorantes-Heredia","year":"2016","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2017.08.024_bib0015","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.5301\/tj.5000276","article-title":"Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin","volume":"101","author":"Hwang","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.lungcan.2017.08.024_bib0020","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.08.024_bib0025","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.024_bib0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.08.024_bib0035","doi-asserted-by":"crossref","first-page":"34300","DOI":"10.18632\/oncotarget.5549","article-title":"Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2017.08.024_bib0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2017.08.024_bib0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdw636","article-title":"Drug-sensitive FGFR3 mutations in lung adenocarcinoma","volume":"28","author":"Chandrani","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.08.024_bib0050","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-14-1337","article-title":"Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma","volume":"20","author":"Capelletti","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.08.024_bib0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/onc.2016.216","article-title":"FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR\/ERK signaling","volume":"36","author":"Daly","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2017.08.024_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lungcan.2017.07.006","article-title":"Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients","volume":"111","author":"Ou","year":"2017","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T22:32:33Z","timestamp":1602887553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217304993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":12,"alternative-id":["S0169500217304993"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.024","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}